Please login to the form below

Not currently logged in
Email:
Password:

DLBCL

This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.

CAR-T player Autolus seeks $100m from follow-on financing

CAR-T player Autolus seeks $100m from follow-on financing

in paediatric ALL and diffuse large B cell lymphoma (DLBCL), as well as to continue development of two other CAR-Ts: anti-BCMA/TACI therapy AUTO2 for multiple myeloma and AUTO4

Latest news

  • CMS proposes coverage scheme for CAR-T therapies CMS proposes coverage scheme for CAR-T therapies

    The first CAR-T to be approved by the FDA was Novartis’ Kymriah (tisagenlecleucel) for B-cell precursor acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL), with Gilead ... Sciences’ Yescarta (axicabtagene ciloleucel)

  • CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

    Novartis agrees pricing deal with NHS England. NICE has today approved Novartis’ CAR-T therapy Kymriah for adults with diffuse large B-cell lymphoma (DLBCL), an aggressive form of blood cancer. ... with its rival, Gilead's Yescarta, in the key DLBCL

  • Novartis aims for 10 blockbuster launches by 2020 Novartis aims for 10 blockbuster launches by 2020

    countries, while Australia approved both its adult DLBCL and children and adolescent ALL indications in December. ... Schaffert declined to give a projection for Kymriah revenues in 2019, but said the company was confident of strong growth thanks to the

  • Novartis buys CellforCure to bolster cell, gene therapy Novartis buys CellforCure to bolster cell, gene therapy

    and adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

  • CAR-Ts take centre stage as ASH18 comes to a close CAR-Ts take centre stage as ASH18 comes to a close

    Similarly, CAR-T pioneer Novartis reported longer-term data on Kymriah (tisagenlecleucel) in children with r/r ALL and adults with r/r diffuse large B-cell lymphoma (DLBCL) that it ... Longer-term follow-up from the JULIET study in DLBCL found a 64%

More from news
Approximately 7 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party

  • Deal Watch January 2018

    pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).  According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics